Collection of Biological Specimens and Associated Health Information
1 other identifier
observational
10,000
1 country
1
Brief Summary
The purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. Researchers may use this database to discover new ways to detect and treat cancer and other diseases. Future studies may use stored blood samples to discover how genes affect health and disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 11, 2024
CompletedFirst Posted
Study publicly available on registry
April 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2034
ExpectedApril 17, 2024
April 1, 2024
1 year
April 11, 2024
April 11, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Biorepository
The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of genetic factors in the biological mechanisms of diseases, including cancer, and treatment outcomes.
10 years
Study Arms (1)
Oncology
Adults (aged 18 or older) who have an active cancer diagnosis with confirmatory pathology results indicating solid tumor and/or hematologic malignancy.
Eligibility Criteria
Adults who have an active cancer diagnosis with confirmatory pathology results indicating solid tumor and/or hematologic malignancy
You may qualify if:
- Are patients of participating study site clinics/clinical groups
- Are adults (aged 18 or older)
- Have an active cancer diagnosis with confirmatory pathology results indicating solid tumor and/or hematologic malignancy
- Participants may have other active diagnoses with confirmatory clinical results
You may not qualify if:
- Individuals who lack the capacity to provide informed consent
- Individuals known to be prisoners at time of biological specimen collection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ovation.io, Inc.lead
Study Sites (1)
Ovation.io
Portland, Maine, 04101, United States
Biospecimen
Whole Blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pauline Gee, PhD
VP, Clinical Affairs, Ovation.io
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 11, 2024
First Posted
April 17, 2024
Study Start
April 1, 2024
Primary Completion
April 1, 2025
Study Completion (Estimated)
April 1, 2034
Last Updated
April 17, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF, CSR
- Time Frame
- Biological specimens and associated data will be stored indefinitely.
- Access Criteria
- All expert determinations performed under this protocol will be pursuant to a business associate agreement and conducted by an individual who has the relevant education and experience to perform a health information de-identification assessment.
All future research requests will be submitted to Ovation.io and reviewed to ensure that they are consistent with the permissions described in the informed consent form by Ovation.io staff. If there is a question regarding whether or not the research request is consistent with the informed consent form and Ovation.io's biorepository policies, Ovation.io will request review and approval by an appropriate IRB. Research teams whose study aims are in concordance with the purpose of the Ovation.io biorepository, may be granted access to specified coded datasets.In the case that a secondary research protocol requires biological specimen analysis to produce the requested dataset, Ovation.io will conduct the analysis on the relevant biological specimens stored in the biorepository and provide the results to the research team in the form of a de-identified dataset.